DOCSLIB.ORG

08/16/2016 CURRICULUM VITAE Jay D. Amsterdam, MD Depression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
08/16/2016 CURRICULUM VITAE Jay D. Amsterdam, MD Depression 08/16/2016 CURRICULUM VITAE Jay D. Amsterdam, MD Depression Research Unit Department of Psychiatry University of Pennsylvania School of Medicine Philadelphia, PA 19104 Phone: 856-448-0780 Fx: 856-428-1392 E-mail: [email protected] University & Medical Education: University: 1966-1970 BA - American Studies - Syracuse University, Syracuse, New York Medicine: 19701974 MD - Jefferson Medical College, Philadelphia, Pennsylvania Postgraduate Training & Fellowship Appointments: 1974 Intern in Obstetrics/Gynecology, Upstate Medical Center, Syracuse, New York 1974 - 1977 Resident in Psychiatry, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 1976 Clinical Attachment, Maudsley Hospital at the Institute of Psychiatry, University of London, England 1976 - 1977 Chief Resident in Psychiatry, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 1977 - 1978 Senior Resident, Psychiatric Research Service, Depression Research Unit, Veterans Administration Medical Center, Philadelphia, PA 1978 - 1979 N.I.M.H. Postdoctoral Fellow in Neuropsychopharmacology - Depression Research Unit, Veterans Administration Hospital, and the Department of Psychiatry, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Academic & Faculty Appointments: 2016 - Professor of Psychiatry (Emeritus) University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania School of Medicine 1992 - 2016 Professor of Psychiatry University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania School of Medicine 1986 - 1992 Associate Professor of Psychiatry University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 1979 - 1986 Assistant Professor of Psychiatry University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Adjunct Academic & Faculty Appointments: 2015 - Professor of Psychiatry (Adjunct) Cooper Medical School of Rowan University Camden, New Jersey 1988 - 1995 Associate Professor (Adjunct) The Wistar Institute of Anatomy, Philadelphia, Pennsylvania 1983 - 1988 Associate Professor of Psychiatry (Adjunct) Thomas Jefferson University, Philadelphia, Pennsylvania 1978 - 1983 Assistant Professor of Psychiatry (Adjunct) Thomas Jefferson University, Philadelphia, Pennsylvania Clinical & Hospital Appointments: 1978 - 2014 Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (Standing Faculty) 1979 - 2016 Director, Depression Research Unit, Hospital of the University of Pennsylvania, Philadelphia, PA 1980 - 1993 Co-Director, Bipolar Disorders & Lithium Clinic 1993 - Director, Bipolar Disorders & Lithium Clinic 1997 - Presbyterian Medical Center, Philadelphia, PA Certification: 1975 Diplomat, National Board of Medical Examiners 1979 Diplomat, American Board of Psychiatry and Neurology 2 Licensure: 1975 - Pennsylvania MD 016480 E 1989 - New Jersey 54109 Research Experience: Psychopharmacology of Affective Disorders Antidepressant Drug Development Investigational Clinical Trials Bipolar Affective Disorders Treatment-resistant Affective Disorders Molecular Brain Imaging Studies Psychoneuroendocrinology of Affective Disorders Psychoimmunovirology of Affective Disorders Clinical Pharmacokinetics Integrative and Botnaical Therapy of Anxiety and Mood Disorders Honors & Awards: 1986 Marie H. Eldredge Award for Research in Affective Disorders, American Psychiatric Association 1988 Curt P. Richter Prize for Research in Psychoneuroendocrinology, International Society of Psychoneuroendocrinology 1989 Fellow of the American Psychiatric Association 1996 Visiting Professor, Karol Marcinkowski Medical Academy of Poznan, Poland 1996 Scholarly Sabbatical, University of Pennsylvania: Serotonin transporter PET imaging 2002 - John Morgan Society 2003 - Distinguished Fellow, American Psychiatric Association 2011 - Distinguished Life Fellow, American Psychiatric Association 2004 - Association of Senior & Emeritus Faculty 2004 - 2005 Philadelphia Top Doc 2005 - 2006 Best Doctors in America 2007 - 2008 Best Doctors in America 2009 - 2010 Best Doctors in America 2011 - 2012 Best Doctors in America 2013 - 2014 Best Doctors in America 2008 - Institute for Translational Medicine & Therapeutics Membership in Professional & Scientific Societies: 1975 - 1990 American Psychiatric Association (General Member) 1990 - 2003 American Psychiatric Association (Fellow) 3 2003 - 2010 American Psychiatric Association (Distinguished Fellow) 2010 - American Psychiatric Association (Distinguished Life Fellow) 1976 - 1981 Royal College of Psychiatrists (Inceptor), London 1975 - Pennsylvania Psychiatric Society 1978 - 2004 International Society of Psychoneuroendocrinology 1982 – 2005 Society of Biological Psychiatry 1983 - 1995 American Federation for Clinical Research 1985 - 1991 Philadelphia Psychiatric Society (Executive Council) 1987 - 1996 American Association for the History of Medicine 1990 - 1994 American Board of Medical Psychotherapists 1989 - 1992 International Society for the Investigation of Stress 1997 - David Mahoney Institute of Neurological Sciences 2002 - John Morgan Scientific Society 2008 - Institute for Translational Medicine & Therapeutics 2016 - International Network for the History of Neuropsychopharmacology Membership on Scientific Journal Editorial Boards: 1986 - 2014 Journal of Affective Disorders - Associate Editor 1987 - 1996 Psychosomatics - Assistant Editor 1995 - Psychiatric Annals - Editorial Advisory Board 1995 - 2000 Depression - Editorial Advisory Board 2000 - 2005 Journal of Bipolar Disorder - Editorial Advisory Board 2000 – 2009 Progress Neuro-Psychopharmacology & Biological Psychiatry – Editorial Board 2001 Psychiatria Polska - Editorial Advisory Board 2005 - Current Drug Therapy - Editorial Advisory Board 2015 - Phytomedicine - Editorial Advisory Board gy Membership on Scientific Journal Review Boards: o Archives of General Psychiatry o American Journal of Psychiatry o Biological Psychiatry o Depression & Anxiety o Journal of Affective Disorders o Journal of Clinical Psychiatry o Journal of Clinical Psychopharmacology o Journal of Neuropsychiatry and Clinical Neuroscience o Progress in Neuro-Psychopharmacology & Biological Psychiatry o Psychoneuroendocrinology o Psychiatric Annals o Psychiatry Research 4 o Psychosomatics o Psychobiology o Psychiatry Research Neuroimaging o Current Drug Therapy o PhytoMedicine Membership on Extramural Advisory Committees: o Program Committee, IV World Congress of Biological Psychiatry (1984-5); o Scientific Advisory Committee, Second International Conference on Viruses, Immunity, and Mental Health (1988); o Program Director, Organizing Committee, First International Conference on Refractory Depression (1988); o Committee on Membership, Society of Biological Psychiatry (1988-91); o NIMH Consensus Panel on Resistant Depression, National Institutes of Health (1989); o Chair, Clinical Research Resource Committee, Philadelphia Psychiatric Society (1989-94); o APA Mood Disorders Review Group for DSM-IV, American Psychiatric Association (1989); o NIMH Workshop Committee on Refractory Depression. NIMH (1990); o NIH Special Emphasis Panel Review Group for Chronic Fatigue Syndrome (CFS) Center Grants, National Institutes of Health (August, 1991); o Organizing Committee, 2nd International Congress on Refractory Depression (1990-92); o Program Director, Organizing Committee, 3rd International Conference on Refractory Depression (1992-95); o NIH Advisory Panel to the Project on Informed Consent, Human Research Ethics Group (1996); o Expert Consensus Panel, International Consensus Conferences on Treatment- Resistant Depression (1996-97); o Scientific Advisory Panel on Premenstrual Dysphoric Disorder (PMDD), Society for the Advancement of Women's Health Research (1998); o Expert Panel on Neuroendocrine Aspects of Chronic Fatigue Syndrome (CFS), Chronic Fatigue and Immune Disorder Syndrome Association (in conjunction with the Center for Disease Control (CDC) and the National Institutes of Health (NIH)) (2001) o Expert Reviewer, Practice Guideline for the Treatment of Patients With Bipolar Disorder, Work Group on Bipolar Disorder of the American Psychiatric Association (2001) o Expert Panel on Immunological Aspects of Chronic Fatigue Syndrome (CFS), Chronic Fatigue and Immune Disorder Syndrome Association (in conjunction with the Center for Disease Control (CDC) and the National Institutes of Health (NIH)) (2001) o Consultant, Information Television Network, Project on Depression for Public Television (2003-2004) o NIMH Special Emphasis Panel Review Group for Translational Research Grants in Mental Disorders, National Institutes of Mental Health (October 28, 2005) o NIMH Special Emphasis Panel Review Group for Educational Research Grants in Mental Health, National Institutes of Mental Health (March 13, 2006) 5 o Advisory Committee, INSIGHT Integrated CME Initiative on Depression, University of Pennsylvania School of Medicine Office of Continuing Medical Education (2006-2007) o International Society for Bipolar Disorders (ISBD) Task Force report on antidepressant use in bipolar disorders o International Society for Bipolar Disorders (ISBD) Task Force report on lithium use in bipolar disorder Past Membership on Pharmaceutical Industry Scientific Panels: o Eli Lilly and Company o Somerset Pharmaceuticals, Inc. o Organon Pharmaceuticals, Inc. o Lundbeck Pharmaceuticals (Denmark) o Bristol Myers Squibb, Inc. o Janssen Pharmaceuticals, Inc. o SK Bio-Pharmaceutical, Inc. o Pfizer Pharmaceuticals, Inc. o Wyeth-Ayerst Pharmaceuticals, Inc. o UCB Pharma, Inc.
Load more

Recommended publications
  • 1 'New/Designer Benzodiazepines'
    1 ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports 2 Laura Orsolini*1,2,3, John M. Corkery1, Stefania Chiappini1, Amira Guirguis1, Alessandro Vento4,5,6,7, 3 Domenico De Berardis3,8,9, Duccio Papanti1, and Fabrizio Schifano1 4 5 1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical 6 Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK. 7 2 Neomesia Mental Health, Villa Jolanda Hospital, Jesi, Italy. 8 3 Polyedra, Teramo, Italy. 9 4 NESMOS Department (Neurosciences, Mental Health and Sensory Organs), Sapienza University – Rome, School of 10 Medicine and Psychology; Sant’Andrea Hospital, Rome, Italy 11 5 School of psychology - G. Marconi Telematic University, Rome, Italy 12 6 Addictions Observatory (ODDPSS), Rome, Italy 13 7 Mental Health Department - ASL Roma 2, Rome, Italy 14 8 Department of Neuroscience, Imaging and Clinical Science, Chair of Psychiatry, University of “G. D’Annunzio”, Chieti, 15 Italy. 16 9 NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4 17 Teramo, Italy. 18 19 Corresponding author: 20 Laura Orsolini, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life 21 and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK; Villa Jolanda Hospital, Neomesia 22 Mental Health, Villa Jolanda, Italy; Polyedra, Teramo, Italy; E-mail address: [email protected]. Tel.: (+39) 392 23 3244643. 24 25 Conflicts of Interest 26 The authors declare that this research was conducted in the absence of any commercial or financial relationships 27 that could be construed as a potential conflict of interest.
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,119,196 B2 Cook Et Al
    US007 119196B2 (12) United States Patent (10) Patent No.: US 7,119,196 B2 Cook et al. (45) Date of Patent: Oct. 10, 2006 (54) ANXIOLYTIC AGENTS WITH REDUCED Armin Walser, et al., “Triazolobenzo- and Triazolothienodiazepines SEDATIVE AND ATAXC EFFECTS as Potent Antagonists of Platelet Activating Factor,” “Journal of Medicinal Chemistry,” 1991, pp. 1209-1221, vol. 34, No. 3, Ameri (75) Inventors: James M. Cook, Whitefish Bay, WI can Chemistry Society. (US); Qi Huang, Moorpark, CA (US); Qi Huang, “Part One: A Chemical and Computer Assisted Approach to Pharmacophore/Receptor Models for GABAaBZ Receptor Sub Xiaohui He, San Diego, CA (US); types; Part Two: Predictive Models for GABAaBZR Subtypes Via Xioayan Li, Milwaukee, WI (US); Comparative Molecular Field Analysis.” DISSERTATION, UW Jianming Yu, Princeton, NJ (US); Milwaukee, 1998, pp. 1-296. Dongmei Han, Milwaukee, WI (US); Shu Yu, et al., “Studies in the Search for a5 Subtype Selective Snjezana Lelas, Middletown, CT (US); Agonists for GABAaBZR Sites,” “Medicinal Chemistry Research.” John F. McElroy, Wilmington, DE 1999, pp. 71-88, Birkhauser Boston. (US) Qi Huang, et al., “Pharmacophore Receptor Models for GABAa? BZR Subtypes (alB3y2, aSB3y2, and aoB3y2) via a Comprehensive (73) Assignee: Wisys Technology Foundation, Inc., Ligand Mapping Approach.” “J. Med. Chem.” 2000, pp. 71-95, Madison, WI (US) American Chemical Society. Xiaohui He, et al., “Pharmacophore/Receptor Models for GABAa? (*) Notice: Subject to any disclaimer, the term of this BZRa2B3y2, a3B3y2 and a4B3y2 Recombinant Subtypes. Induced patent is extended or adjusted under 35 Volume Analysis and Comparison to alB3y2, aSB3y2 and aoB3y2 U.S.C. 154(b) by 198 days.
    [Show full text]
  • Spontaneous Withdrawal from the Triazolobenzodiazepine Alprazolam Increases Cortical Corticotropin-Releasing Factor Mrna Expression
    The Journal of Neuroscience, October 20, 2004 • 24(42):9303–9312 • 9303 Behavioral/Systems/Cognitive Spontaneous Withdrawal from the Triazolobenzodiazepine Alprazolam Increases Cortical Corticotropin-Releasing Factor mRNA Expression Kelly H. Skelton, Charles B. Nemeroff, and Michael J. Owens Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322 Corticotropin-releasing factor (CRF) is the major physiologic regulator of the hypothalamic–pituitary–adrenal (HPA) axis and plays a key role in coordinating the mammalian stress response. Substantial data implicates hyperactivity of CRF neuronal systems in the pathophysiology of depression and anxiety disorders. Enhanced CRF expression, release, and function have also been demonstrated during acute withdrawal from several drugs of abuse. Previous studies revealed that chronic administration of the anxiolytic alprazolam reduced indices of CRF and CRF1 receptor function. Conversely, measures of urocortin I and CRF2 receptor function were increased. To further scrutinize these findings, we sought to determine whether CRF neuronal systems are activated during spontaneous withdrawal from the triazolobenzodiazepine alprazolam in dependent rats and to characterize the time course, extent, and regional specificity of the patterns of activation. After 14 d of alprazolam administration (90 mg ⅐ kg Ϫ1 ⅐ d Ϫ1), spontaneous withdrawal produced activation of the HPA axis, as well as suppression of food intake and weight loss that peaked 24–48 hr after withdrawal. Remarkably, CRF mRNA expression in the cerebral cortex was markedly Ͼ ( 300%) increased over the same time period. Other indices of CRF-CRF1 and urocortin I-CRF2A function, altered by chronic alprazolam treatment as previously described, returned to pretreatment levels over 96 hr.
    [Show full text]
  • Download (6MB)
    https://theses.gla.ac.uk/ Theses Digitisation: https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ This is a digitised version of the original print thesis. Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] THE SOLID-PHASE EXTRACTION OF DRUGS FROM BIOLOGICAL FLUIDS. Thesis submitted in accordance with the requirements of the University of Glasgow for the degree of Doctor of Philosophy by Christine Mary Moore. BSc (Hons.), MSc., C.Chem. M.R.S.C. Department of Forensic Medicine and Science June 1989 © Christine Mary Moore, 1989. ProQuest Number: 10999233 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10999233 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
    [Show full text]
  • Basic and Clinical Aspects of Depression
    Abstracts of Poster Presentations 259 31.01.01 PHARMACOTHERAPY, PSYCHOTHERAPY, AND PSYCHOEDUCATIONAL INTERVENTIONS: EFFICACY IN RECURRENT DEPRESSION POSTER E. Frank, and D. J. Kupfer We are currently engaged in a study of maintenance treatments for PRESENTATION recurrent unipolar depression which compares the efficacy of psychotherapy, pharmacotherapy and their combination. Rather 31.01 than focusing exclusively on the number of recurrences in each of the experimental conditions, we have also been concerned with the quality of patients' lives between episodes and with the !ength of the symptom-free interval. The three-year maintenance phase of our study is still in progress; therefore, final results will not be available for another 18 months to 2 years. We can, however, discuss the information available on Basic and Clinical Aspects those 62 patients who have already experienced a recurrence of illness and for whom the blind has been broken. While the majority of Depression of recurrences have been experienced by patients in the non- medication conditions, it would appear that, with or without medication, psychotherapy has had a significant effect in delaying the onset of a new episode. At this point in time, however, we have little evidence that continued psychotherapy adds to the generally good quality of patients' social functioning in symptom-free interval. A full understanding of the additive and interactive effects of pharmacotherapy and psychotherapy in the treatment of recurrent depression must await the completion of this study
    [Show full text]
  • QSAR) Model to Predict GABA-A Receptor Binding of Newly Emerging Benzodiazepines
    Accepted Manuscript The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines Laura Waters, Kieran R. Manchester, Peter D. Maskell, Shozeb Haider, Caroline Haegeman PII: S1355-0306(17)30154-5 DOI: doi:10.1016/j.scijus.2017.12.004 Reference: SCIJUS 710 To appear in: Science & Justice Received date: 6 November 2017 Revised date: 13 December 2017 Accepted date: 16 December 2017 Please cite this article as: Laura Waters, Kieran R. Manchester, Peter D. Maskell, Shozeb Haider, Caroline Haegeman , The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Scijus(2017), doi:10.1016/j.scijus.2017.12.004 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines Laura Waters1*, Kieran R Manchester1, Peter D Maskell2, Shozeb Haider3, Caroline Haegeman3 1School of Applied Sciences, University of Huddersfield, Huddersfield, UK 2School of Science, Engineering and Technology, Abertay University, Dundee, UK 3School of Pharmacy, University College London, London, UK *Author for correspondence.
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • The Use of a Quantitative Structure-Activity Relationship (QSAR) Model to Predict GABA-A Receptor Binding of Newly Emerging Benzodiazepines
    University of Huddersfield Repository Waters, Laura J., Manchester, Kieran R., Maskell, Peter D., Haegeman, Caroline and Haider, Shozeb The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines Original Citation Waters, Laura J., Manchester, Kieran R., Maskell, Peter D., Haegeman, Caroline and Haider, Shozeb (2018) The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Science and Justice. ISSN 1355- 0306 This version is available at http://eprints.hud.ac.uk/id/eprint/34383/ The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided: • The authors, title and full bibliographic details is credited in any copy; • A hyperlink and/or URL is included for the original metadata page; and • The content is not changed in any way. For more information, including our policy and submission procedure, please contact the Repository Team at: [email protected]. http://eprints.hud.ac.uk/ *Highlights (for review) The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines There is a deficiency in the pharmacological data available for new benzodiazepines.
    [Show full text]
  • FLUALPRAZOLAM (Street Name: Flualp)
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section June 2020 FLUALPRAZOLAM (Street Name: Flualp) Introduction: associated with coma. The onset of action of flualprazolam Flualprazolam is structurally related to the triazolo- following oral administration is reported to be 10-30 minutes. benzodiazepine, alprazolam. As a class of drugs, Flualprazolam has a long duration of action (6-14 hour) benzodiazepines produce central nervous system (CNS) compared to the relatively short acting alprazolam. depression and are commonly used to treat, panic disorders, According to the United Nations Office on Drugs and Crime anxiety, and insomnia. The United States Food and Drug (UNODC) Early Warning Advisory on NPS Toxicology Portal Administration has not approved flualprazolam for therapeutic (Tox-Portal), an online tool utilized to collect toxicological data use. and harm associated with the use of novel psychoactive substances, 42 cases involving flualprazolam were reported in Licit Uses: 2019. Of the 42 cases reported to UNODC, 40 cases originated Flualprazolam does not currently have an accepted medical from the United States. In five of these U.S. cases, flualprazolam use in the United States. was determined to be causal to the event that precipitated reporting. Chemistry: Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H- Illicit Uses: Flualprazolam is generally abused for its sedative/hypnotic [1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a triazolobenzo- effects. Reports from online drug user forums describe it to be diazepine and is structurally similar to alprazolam. Flualprazolam similar to clonazepam and alprazolam. is composed of a benzene ring fused to a seven-membered 1,4- diazepine ring.
    [Show full text]
  • One-Pot Synthesis of Triazolobenzodiazepines Through
    Communicationmolecules One-Pot Synthesis of Triazolobenzodiazepines CommunicationThrough Decarboxylative [3 + 2] Cycloaddition of One-Pot Synthesis of Triazolobenzodiazepines ThroughNonstabilized Decarboxylative Azomethine [3 Ylides + 2] Cycloaddition and Cu-Free ofClick NonstabilizedReactions Azomethine Ylides and Cu-Free Click Reactions Xiaoming Ma 1,†, Xiaofeng Zhang 2, †, Weiqi Qiu 2, Wensheng Zhang 3, Bruce Wan 2, Jason Evans 2 and Wei Zhang 2,* Xiaoming Ma 1,†, Xiaofeng Zhang 2,†, Weiqi Qiu 2, Wensheng Zhang 3, Bruce Wan 2, Jason1 School Evans of Pharmaceutical2 and Wei Zhang Engineering2,* and Life Science, Changzhou University, Changzhou 213164, China; [email protected] 1 School of Pharmaceutical Engineering and Life Science, Changzhou University, Changzhou 213164, China; 2 Department of Chemistry, University of Massachusetts Boston, 100 Morrissey Boulevard, Boston, MA [email protected] 02125, USA. [email protected] (X.Z.); [email protected] (W.Q.); [email protected] 2 Department of Chemistry, University of Massachusetts Boston, 100 Morrissey Boulevard, Boston, MA 02125, (B.W.); [email protected] (J.E.) USA; [email protected] (X.Z.); [email protected] (W.Q.); [email protected] (B.W.); 3 [email protected] of Science, Jiaozuo (J.E.) Teachers’ College, 998 Shanyang Road, Jiaozuo 454100, China; 3 [email protected] of Science, Jiaozuo Teachers’ College, 998 Shanyang Road, Jiaozuo 454100, China; [email protected] ** Correspondence:Correspondence: [email protected]; [email protected];
    [Show full text]
  • A Review of Alprazolam Use, Misuse, and Withdrawal Copyright © 2017 American Society of Addiction Medicine
    REVIEW A Review of Alprazolam Use, Misuse, and Withdrawal Nassima Ait-Daoud, MD, Allan Scott Hamby, MD, Sana Sharma, MD, and Derek Blevins, MD involved in ED visits related to drug misuse (SAMHSA, Alprazolam is one of the most widely prescribed benzodiazepines for 2013). 10/25/2018 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD38k+bDukTnmaPqdvLJ6faZl2ZVgRM9M6DN4fDksE+1oUWFvbrFN5vnw== by https://journals.lww.com/journaladdictionmedicine from Downloaded Downloaded the treatment of generalized anxiety disorder and panic disorder. Its Benzodiazepines are implicated in approximately one- clinical use has been a point of contention as most addiction special- third of intentional overdoses or suicide attempts (Henderson from ists consider it to be highly addictive, given its unique psychody- et al., 1993). A database review of poisoning admissions to a https://journals.lww.com/journaladdictionmedicine namic properties which limit its clinical usefulness, whereas many regional toxicology service revealed that when alprazolam primary care physicians continue to prescribe it for longer periods was involved, the median length of stay (LOS) was 19 hours, than recommended. Clinical research data has not fully shed light on which was 1.27 (95% confidence interval [CI] 1.04, 1.54) its ‘‘abuse liability,’’ yet it is one of the most frequently prescribed times longer compared with other benzodiazepines, and benzodiazepines. ‘‘Abuse liability’’ is the degree to which a psycho- patients were 2.06 (95% CI 1.27, 3.33) times more likely active drug has properties that facilitate people misusing it, or to be admitted to the intensive care unit (ICU) compared with becoming addicted to it, and is commonly used in the literature.
    [Show full text]